News - Razadyne ER (Galantamine Hydrobromide), Once-Daily Treatment, Now Available for Patients With Mild to Moderate Alzheimer's DiseaseTITUSVILLE, NJ -- May 23, 2005 -- Razadyne(TM) ER (galantamine hydrobromide), a new once-daily treatment for the symptoms of mild to moderate Alzheimer's disease, is now available by prescription nationwide. The product is marketed by Ortho-McNeil Neurologics, Inc.Approved by the U.S. Food and Drug Administration (FDA) in December 2004, Razadyne ER contains galantamine hydrobromide -- first approved by the FDA in February 2001 as a twice-daily medication, REMINYL(R). In April 2005, the product name was changed to Razadyne. Approximately two million patients have been treated with REMINYL to date. In clinical trials, Razadyne ER provided comparable efficacy, safety, and tolerability to twice-daily galantamine with the convenience of once-daily dosing.
